Answer

IFF (Scent) recovery drivers, 2H evolution for Fine Fragrance vs Consumer Fragrance, and the R&D plan to support 2027

1) Drivers of Scent’s recovery (what management says is actually changing)

A. Fine Fragrance recovery is being managed through Middle East volatility + tough compares

Management explicitly frames Fine Fragrance performance as affected by “uncertainty and volatility” from the Middle East conflict, and notes that the team managed this challenge such that Fine Fragrance was slightly positive even though they expected mid-single-digit growth to be down into the quarter before results. ¹
For the path of recovery through the year, management says the second half should reflect a softer Q3 followed by recovery into Q4, with the key mechanism described as the very large prior-year comp (Q3 Fine Fragrance up ~20% in the prior year). ¹
On the growth-rate framework for Scent, Fine Fragrance (as part of “Scent business recovery”) is guided to be mid-single-digit growth on a second-half basis, with Q3 softer and Q4 stronger. ²

Interpretation grounded in the transcript: the recovery driver for Fine Fragrance is not presented as a sudden demand rebound, but rather as (i) operational/channel management of uncertainty and (ii) the timing of performance versus difficult year-ago comparables, culminating in improving conditions/clear comps in Q4. ¹²

B. Consumer Fragrance recovery is tied to execution, rebuilt R&D go-to-market capability, and market share gains

On Consumer Fragrance, management expects it to sit in the low single-digit range go-forward, after a high single-digit Q2 that will “normalize.” ²
The team attributes the improved trajectory to rebuilding capabilities, specifically: “rebuild the R&D capability go-to-market approach with customers” and “drive market share gains.” ²

Interpretation grounded in the transcript: Consumer Fragrance recovery is described as more “structural” (capability + go-to-market + share gains) rather than primarily a comp/timing story. ²

C. Scent profitability and execution are supported by volumes/productivity (and specifically Scent’s segment mix)

In the Scent segment results cited, Scent delivered sales of $665 million (+8%), with performance driven by double-digit growth in Fragrance Ingredients and high single-digit increase in Consumer Fragrance. ³
The same excerpt links segment profitability improvement to operational levers: Scent profitability was also solid with EBITDA growing 5% to $134 million, primarily driven by volume growth and productivity gains. ³
For the half-year context, management also highlighted that Scent results reflect volume growth and continued productivity gains (general IFF commentary), with segment-led contribution to consolidated growth. ⁴

Interpretation grounded in the transcript: recovery is being operationally reinforced via productivity and volume execution, not just pricing or one-offs. ³⁴

D. Fragrance Ingredients is a key near-term tailwind, but it is expected to normalize

Management says Scent Q2 results were driven in part by Fragrance Ingredients: Fragrance Ingredients grew north of 20%, including leverage from comparing against a period where Fragrance Ingredients was down 10% or more year-ago. ¹
They also state this uplift included strategic capture of sales using the synthetics portfolio amid macro/supply chain conditions (including higher Brent crude prices). ¹
Critically for “recovery drivers,” management expects normalization: as things settle down, growth should shift back toward higher value-added ingredients rather than traditional synthetics, and they believe the normalization is included in the forecast for the second half. ¹

Implication: Fragrance Ingredients is providing strong momentum that supports Scent recovery, while management expects the growth profile to become more “quality” oriented (higher-value ingredients) as normalization occurs. ¹

2) How Fine Fragrance and Consumer Fragrance will evolve in 2H 2026

Fine Fragrance (2H profile)

2H growth guidance: mid-single-digit growth on a second-half basis. ²
Quarter shape: softer in Q3 and stronger in Q4. ²
Reasoning: management points to the Middle East-driven noise and, importantly, the large Q3 prior-year comp (Fine Fragrance grew 20% year-ago Q3), which affects how performance will read sequentially and year-over-year. ¹

Consumer Fragrance (2H profile)

2H growth guidance: low single-digit growth go-forward. ²
Normalization detail: Q2 was strong at a high single-digit number, but management expects this to normalize. ²
Core execution rationale: rebuilding R&D capability and customer go-to-market, plus market share gains. ²

What will likely pressurize year-over-year in the Ingredients line (related but important to the “Scent” recovery total)

Management flags that Fragrance Ingredients (within the Scent segment) is expected to normalize, with slightly under pressure year-over-year performance, because the strong Q2 was unusually strong. ²
They also distinguish this from the middle-term competitive posture: while “not in the second half of this year,” management expects the shift to higher-value natural products to take more time and lead to a stronger competitive position into next year and “the year after.” ²

3) Plan for R&D to support 2027 (what management says about rebuilding capability, pipeline quality, and “leading-edge” development)

A. R&D capability has been materially upgraded over the last ~2.5 years

Management says that 2.5 years ago the R&D pipeline “was not what it should have been” and that today IFF has a “very strong R&D capability,” a great R&D team, and perfumers developing “leading-edge new Fine Fragrances and Consumer Fragrances.” ⁵
They also emphasize the breadth of the R&D platform: a “great pipeline of molecules as well as delivery systems.” ⁵

B. R&D is specifically tied to commercial go-to-market and market share gains

In the forward 2H/into-next-years framework, management links Consumer Fragrance improvement to rebuilding the R&D capability go-to-market approach with customers and driving market share gains. ²

C. Management’s 2027 support is framed as pipeline execution and competitive positioning, not just incremental spending

While the excerpt doesn’t state an explicit “2027 R&D spend” number, management does connect the improved R&D system to achieving a strong competitive position “as we go into next year and the year after” (which would include 2027). ²
The CEO’s comments reinforce that the current state is the result of closing R&D pipeline gaps (“addressing our gaps”), while acknowledging there is still more work to do—i.e., it’s an ongoing capability build intended to sustain the future competitive position. ⁵

Bottom line: The R&D plan described is capability rebuilding + leading-edge product development + a strengthened molecule/delivery-system pipeline, tied directly to customer go-to-market and market share gains; management expects this to support a stronger competitive position into 2027 (framed as “next year and the year after”). ⁵²

Summary (direct answer)

Drivers of Scent recovery: management attributes the recovery to (i) Fine Fragrance being stabilized through Middle East volatility while navigating difficult comps with recovery expected into Q4, ¹ (ii) Consumer Fragrance normalizing from a strong quarter but remaining supported by rebuilt R&D go-to-market capability and market share gains, ² and (iii) the broader Scent momentum being aided by Fragrance Ingredients strength in Q2 that is expected to normalize in 2H toward higher value-added ingredients. ¹²
2H evolution: Fine Fragrance is expected to be mid-single-digit for the half with Q3 softer and Q4 stronger, ² while Consumer Fragrance is expected to settle into low single-digit go-forward after high single-digit Q2 strength that normalizes. ²
R&D plan for 2027: IFF states it has rebuilt R&D after earlier pipeline shortfalls, with leading-edge new Fine and Consumer fragrance development, a strong molecule and delivery systems pipeline, and R&D integrated into customer go-to-market—positioning the business for a stronger competitive stance into next year and the year after (including 2027). ⁵²

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

IFF Scent Recovery Fueled by 2H Fine Fragrance Growth and 2027 R&D Push

Sources used

Research question

Answer

IFF (Scent) recovery drivers, 2H evolution for Fine Fragrance vs Consumer Fragrance, and the R&D plan to support 2027

1) Drivers of Scent’s recovery (what management says is actually changing)

A. Fine Fragrance recovery is being managed through Middle East volatility + tough compares

B. Consumer Fragrance recovery is tied to execution, rebuilt R&D go-to-market capability, and market share gains

C. Scent profitability and execution are supported by volumes/productivity (and specifically Scent’s segment mix)

D. Fragrance Ingredients is a key near-term tailwind, but it is expected to normalize

2) How Fine Fragrance and Consumer Fragrance will evolve in 2H 2026

Fine Fragrance (2H profile)

Consumer Fragrance (2H profile)

What will likely pressurize year-over-year in the Ingredients line (related but important to the “Scent” recovery total)

3) Plan for R&D to support 2027 (what management says about rebuilding capability, pipeline quality, and “leading-edge” development)

A. R&D capability has been materially upgraded over the last ~2.5 years

B. R&D is specifically tied to commercial go-to-market and market share gains

C. Management’s 2027 support is framed as pipeline execution and competitive positioning, not just incremental spending

Summary (direct answer)

References

Keep Reading

IFF Scent Recovery Driven by R&D Rebuild and 2H 2026 Outlook and 2027 Plan

Keep Reading

Keep Reading

IFF Scent Recovery Driven by R&D Rebuild and 2H 2026 Outlook and 2027 Plan

IFF Sees Scent Recovery Fueled by R&D Rebuild, H2 Stabilization, and 2027 Plan

IFF's Scent Recovery Gains Momentum in Q2 2026 with R&D Support for 2027

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF Scent Recovery Driven by R&D Rebuild; Q2 2026 H2 Outlook and 2027 Plan

IFF's Scent Recovery Q2 2026 Highlights, H2 Outlook and 2027 R&D Plan

IFF Guides Capex at 5–6% and R&D at 8–9% Post-Divestiture Growth

IFF Scent Recovery Fueled by Q2 Strength, R&D Push, and 2027 Plan

IFF Outlines 5-6% Capex Target and Reinvestment Rhythm Post-Divestiture in 2026

IFF Signals Scent Recovery Driven by R&D Rebuild and 2027 Plan

IFF Scent Recovery Driven by R&D Rebuild, Fragrance Momentum, and 2027 Plan

IFF's Scent Recovery Driven by R&D Rebuild, 2027 Readiness Ahead